Skip to main content

The role of surrogate markers in the management of men with metastatic castration-resistant prostate cancer.

Publication ,  Journal Article
Armstrong, AJ; Ferrari, AC; Quinn, DI
Published in: Clin Adv Hematol Oncol
December 2011

Over the past year, the treatment of metastatic castration-resistant prostate cancer (mCRPC) was dramatically altered with the introduction of several novel agents. One of these agents, the cancer immunotherapy sipuleucel-T, represents a major change in the treatment paradigm for patients with mCRPC. While immunotherapies such as sipuleucel-T are associated with a significant improvement in overall survival, many questions remain regarding their use. Specifically, there are questions as to which endpoints should be used to measure benefit with immunotherapy. Clinical trials of sipuleucel-T demonstrated that the traditional endpoints normally used in mCRPC trials, such as progression-free survival, are not good measures of response with immunotherapy. However, measurement of overall survival is difficult in the clinical trial setting. There is now a major interest in the identification of surrogate biomarkers of survival that could allow the benefit of novel agents to be more precisely determined. Many potential biomarkers have been identified, often from studies showing their prognostic potential. In this roundtable, experts discuss the role of biomarkers in measuring response to immunotherapy for men with mCRPC.

Duke Scholars

Published In

Clin Adv Hematol Oncol

ISSN

1543-0790

Publication Date

December 2011

Volume

9

Issue

12 Suppl 28

Start / End Page

1 / 14

Location

United States

Related Subject Headings

  • Prostatic Neoplasms
  • Oncology & Carcinogenesis
  • Neoplasm Metastasis
  • Male
  • Humans
  • Drug Resistance, Neoplasm
  • Castration
  • Biomarkers, Tumor
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Armstrong, A. J., Ferrari, A. C., & Quinn, D. I. (2011). The role of surrogate markers in the management of men with metastatic castration-resistant prostate cancer. Clin Adv Hematol Oncol, 9(12 Suppl 28), 1–14.
Armstrong, Andrew J., Anna C. Ferrari, and David I. Quinn. “The role of surrogate markers in the management of men with metastatic castration-resistant prostate cancer.Clin Adv Hematol Oncol 9, no. 12 Suppl 28 (December 2011): 1–14.
Armstrong AJ, Ferrari AC, Quinn DI. The role of surrogate markers in the management of men with metastatic castration-resistant prostate cancer. Clin Adv Hematol Oncol. 2011 Dec;9(12 Suppl 28):1–14.
Armstrong, Andrew J., et al. “The role of surrogate markers in the management of men with metastatic castration-resistant prostate cancer.Clin Adv Hematol Oncol, vol. 9, no. 12 Suppl 28, Dec. 2011, pp. 1–14.
Armstrong AJ, Ferrari AC, Quinn DI. The role of surrogate markers in the management of men with metastatic castration-resistant prostate cancer. Clin Adv Hematol Oncol. 2011 Dec;9(12 Suppl 28):1–14.

Published In

Clin Adv Hematol Oncol

ISSN

1543-0790

Publication Date

December 2011

Volume

9

Issue

12 Suppl 28

Start / End Page

1 / 14

Location

United States

Related Subject Headings

  • Prostatic Neoplasms
  • Oncology & Carcinogenesis
  • Neoplasm Metastasis
  • Male
  • Humans
  • Drug Resistance, Neoplasm
  • Castration
  • Biomarkers, Tumor